Sandbox john: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
(9 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Testing area== | |||
==Multiple Tables== | ==Multiple Tables== | ||
*0. | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | |||
|+ | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Disease}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Findings}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[DISEASE NAME]]''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | PRESENTS WITH_____ | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | '''DISEASE NAME''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" |PRESENTS WITH____ | |||
|- | |||
|} | |||
*1. | *1. | ||
Line 176: | Line 193: | ||
|} | |} | ||
*4. | |||
{| | {| | ||
| valign=top | | | valign=top | | ||
{| style="cellpadding=0; cellspacing= 0; width: 290px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Group A (May be sent home)}} | |||
{| | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | |||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; | |<div class="mw-customtoggle-tableA1" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Group criteria}}</div> | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | | | valign=top | | ||
{| class="mw-collapsible mw-expanded" id="mw-customcollapsible-tableA1" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients who do not have warning signs | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | PLUS | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Able to tolerate adequate volumes of oral fluids <BR> OR <BR> ❑ Able to pass urine at least once every 6 hours | |||
|} | |} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; | |<div class="mw-customtoggle-tableA2" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Laboratory tests}}</div> | ||
|- | |- | ||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableA2" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Complete blood count <BR> ❑ Hematocrit (Hct) | |||
|} | |||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; | |<div class="mw-customtoggle-tableA3" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Management}}</div> | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableA3" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Adequate bed rest <BR> ❑ Adequate fluid intake <BR> ❑ Acetaminophen (Paracetamol) | |||
|} | |||
|- | |- | ||
| | |<div class="mw-customtoggle-tableA4" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Monitoring}}</div> | ||
|- | |- | ||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableA4" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients with stable Hct may be sent home. <BR> ❑ Daily review for disease progression: <BR> ❑ Decreasing white blood cell count <BR> ❑ Defervescence <BR> ❑ Warning signs (until out of critical period) <BR> ❑ Immediate return to hospital if development of any warning signs <BR> ❑ Written advice for management | |||
|} | |} | ||
|} | |} | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="cellpadding=0; cellspacing= 0; width: 290px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Group B (Referred for in-hospital care)}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; | |<div class="mw-customtoggle-tableB1" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Group criteria}}</div> | ||
|- | |- | ||
| valign=top | | |||
{| class="mw-collapsible mw-expanded" id="mw-customcollapsible-tableB1" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients with <u>any</u> of the warning signs: <BR> ❑ Abdominal pain or tenderness <BR> ❑ Persistent vomiting <BR> ❑ Clinical fluid accumulation <BR> ❑ Mucosal bleed <BR> ❑ Lethargy, restlessness <BR> ❑ Liver enlargment >2 cm <BR> ❑ Increase in hematocrit with rapid decrease in platelet count | |||
|} | |||
|- | |- | ||
| style="font-size: 90%; | |<div class="mw-customtoggle-tableB2" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Laboratory tests}}</div> | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableB2" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Complete blood count <BR> ❑ Hematocrit (Hct) | |||
|} | |} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; | |<div class="mw-customtoggle-tableB3" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Management}}</div> | ||
|- | |- | ||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableB3" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Obtain reference Hct before fluid therapy <BR> ❑ Give isotonic solutions such as 0.9 % saline or Ringer’s Lactate <BR> ❑ Start with 5–7 ml/kg/h for 1–2 h <BR> ❑ Then reduce to 3–5 ml/kg/h for 2–4 h <BR> ❑ Then reduce to 2–3 ml/kg/h or less according to clinical response | |||
|- | |- | ||
| style="font-size: 90%; | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Reassess clinical status and repeat Hct | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If Hct remains the same or rises only minimally: <BR> ❑ Continue with 2–3 ml/kg/h for another 2–4 h <BR> ❑ If worsening of vital signs and rapidly rising Hct: <BR> ❑ Increase rate to 5–10 ml/kg/h for 1–2 h | ||
|- | |- | ||
| style="font-size: 90%; | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Adjust fluid infusion rates | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Reduce intravenous fluids gradually when: <BR> ❑ Adequate urine output and/or fluid intake <BR> ❑ Hct deceases below the baseline value in a stable patient | ||
|} | |} | ||
|- | |- | ||
| | |<div class="mw-customtoggle-tableB4" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Monitoring}}</div> | ||
| | |||
|- | |- | ||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableB4" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Vital signs and peripheral perfusion (q1–4 until out of critical phase): <BR> ❑ Urine output (4–6 hourly) <BR> ❑ Hct (before and after fluid replacement, then 6–12 hourly) <BR> ❑ Blood glucose <BR> ❑ Renal function <BR> ❑ Liver function <BR> ❑ Coagulation profile | |||
|} | |} | ||
|} | |} | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="cellpadding=0; cellspacing= 0; width: 290px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Group C (Require emergency treatment)}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; | |<div class="mw-customtoggle-tableC1" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Group criteria}}</div> | ||
|- | |- | ||
| valign=top | | |||
{| class="mw-collapsible mw-expanded" id="mw-customcollapsible-tableC1" | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients with <u>any</u> of the warning signs: <BR> ❑ Abdominal pain or tenderness <BR> ❑ Persistent vomiting <BR> ❑ Clinical fluid accumulation <BR> ❑ Mucosal bleed <BR> ❑ Lethargy, restlessness <BR> ❑ Liver enlargment >2 cm <BR> ❑ Increase in hematocrit with rapid decrease in platelet count | |||
|} | |||
|- | |- | ||
| style="font-size: 90%; | |<div class="mw-customtoggle-tableC2" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Laboratory tests}}</div> | ||
|- | |- | ||
| valign=top | | | valign=top | | ||
{| | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableC2" | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Complete blood count <BR> ❑ Hematocrit (Hct) <BR> ❑ Other organ function tests as indicated | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; | |||
|} | |} | ||
|- | |- | ||
| style="font-size: 90%; | |<div class="mw-customtoggle-tableC3" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF| ▸ Management}}</div> | ||
|- | |- | ||
| valign=top | | | valign=top | | ||
{| | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableC3" | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Management of compensated shock | |||
|- | |- | ||
| style=" | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Resuscitation with isotonic crystalloid at 5–10 ml/kg/h over 1 hour | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient improves: <BR> ❑ Reduce IV fluids gradually to 5–7 ml/kg/h for 1–2 h <BR> ❑ Then to 3–5 ml/kg/h for 2–4 h <BR> ❑ Then to 2–3 ml/kg/h for 2–4 h <BR> ❑ Then reduced further depending on hemodynamic status <BR> ❑ IV fluids can be maintained for up to 24–48 h | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient is still unstable: <BR> ❑ Check Hct after first bolus <BR> ❑ If Hct increases: repeat a second bolus at 10–20 ml/kg/h for 1 h <BR> ❑ If Hct decreases: transfuse as soon as possible | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Management of hypotensive shock | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Resuscitation with crystalloid/colloid at 20 ml/kg for 15 min | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient improves: <BR> ❑ Control rate at 10 ml/kg/h for 1 h, then reduce gradually | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient is still unstable: <BR> ❑ Review the HCT taken before the first bolus <BR> ❑ If HCT was low: transfuse as soon as possible <BR> ❑ If HCT was high: IV colloids at 10–20 ml/kg for 0.5–1 h <BR> ❑ If patient is improving: reduce the rate to 7–10 ml/kg/h for 1–2 h | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient is still unstable after second bolus: <BR> ❑ If HCT decreases: transfuse as soon as possible <BR> ❑ If HCT increases: continue colloid at 10–20 ml/kg for 1 h | ||
|- | |- | ||
| style="font-size: 90%; | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Management of hemorrhagic complications | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Give 5–10 ml/kg of packed red cells or 10–20 ml/kg of whole blood | |||
|} | |} | ||
|} | |} | ||
|} | |} |
Latest revision as of 17:44, 14 July 2014
Testing area
Multiple Tables
- 0.
Disease | Findings |
---|---|
DISEASE NAME | PRESENTS WITH_____ |
DISEASE NAME | PRESENTS WITH____ |
- 1.
Unfavorable Prognostic Factors |
▸ Presenting with encephalopathy or coma |
▸ Younger than 10 years or elderly |
▸ Late start of antibiotics |
▸ Sterile cultures |
Favorable prognostic factors |
▸ Craniotomy instead of burr holes as surgical procedure |
▸ Early treatment |
▸ Young age (optimal between 10-20 years) |
▸ Patient presents awake, alert and oriented |
▸ Source of infection: paranasal sinuses |
▸ Aerobic streptococci isolated in culture |
▸ Aerobic streptococci as single pathogen |
- 2.
Unfavorable Prognostic Factors |
---|
▸ Presenting with encephalopathy or coma |
▸ Younger than 10 years or elderly |
▸ Late start of antibiotics |
▸ Sterile cultures |
Favorable Prognostic Factors |
▸ Craniotomy instead of burr holes as surgical procedure |
▸ Early treatment |
▸ Young age (optimal between 10-20 years) |
▸ Patient presents awake, alert and oriented |
▸ Source of infection: paranasal sinuses |
▸ Aerobic streptococci isolated in culture |
▸ Aerobic streptococci as single pathogen |
- 3.
Cardiovascular | No underlying causes |
Chemical/Poisoning | No underlying causes |
Dental | No underlying causes |
Dermatologic | No underlying causes |
Drug Side Effect | No underlying causes |
Ear Nose Throat | No underlying causes |
Endocrine | No underlying causes |
Environmental | No underlying causes |
Gastroenterologic | No underlying causes |
Genetic | No underlying causes |
Hematologic | No underlying causes |
Iatrogenic | No underlying causes |
Infectious Disease | No underlying causes |
Musculoskeletal/Orthopedic | No underlying causes |
Neurologic | No underlying causes |
Nutritional/Metabolic | No underlying causes |
Obstetric/Gynecologic | No underlying causes |
Oncologic | No underlying causes |
Ophthalmologic | No underlying causes |
Overdose/Toxicity | No underlying causes |
Psychiatric | No underlying causes |
Pulmonary | No underlying causes |
Renal/Electrolyte | No underlying causes |
Rheumatology/Immunology/Allergy | No underlying causes |
Sexual | No underlying causes |
Trauma | No underlying causes |
Urologic | No underlying causes |
Miscellaneous | No underlying causes |
- 4.
|
|
|